KOR

e-Article

FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma
Document Type
Journal
Source
ANNALS OF ONCOLOGY; MAY 2021, 32 5, p609-p619, 11p.
Subject
Language
English
ISSN
15698041